FindTrial
Sign In

The efficacy and safety of amoxicillin-voronazan dual therapy and furazolidone-containing bismuth quadruple therapy for 14 days in Helicobacter pylori eradication: A single center, open-labeled, randomized, non-inferior clinical trial

The efficacy and safety of amoxicillin-voronazan dual therapy and furazolidone-containing bismuth quadruple therapy for 14 days in Helicobacter pylori eradication: A single center, open-labeled, randomized, non-inferior clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064872
Enrollment
Unknown
Registered
2022-10-20
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori

Interventions

Group 1:amoxicillin-vonoprazan (L-VA) dual therapy consisted of 1000 mg amoxicillin capsules twice daily and 20 mg VPZ Fumarate Tablets twice daily for 14 days
Group 2:1000 mg amoxicillin capsules twice daily+Furazolidone 100mg twice daily+bismuth potassium citrate granules 600mg twice daily+vonoprazan 20mg twice daily for 14 days

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Consecutive Helicobacter pylori-infected subjects aged from 18 to 70 years without eradication history.

Exclusion criteria

Exclusion criteria: 1. Allergic to amoxicillin or vonora; 2. Acute upper gastrointestinal bleeding, gastric cancer or other tumors, Z-E syndrome, history of gastrectomy; 3. Serious illness; 4. Pregnant or breastfeeding; 5. Take proton pump inhibitors or antibiotics for one month; 6. Not agreeing to participate in the study.

Design outcomes

Primary

MeasureTime frame
eradication rate;—

Secondary

MeasureTime frame
the incidence of adverse events;—

Countries

China

Contacts

Public ContactLyu Nonghua

The First Affiliated Hospital of Nanchang University

lunonghua@ncu.edu.cn+86 13707086809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026